Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Assessment of Neoadjuvant Intervention With Metformin Against Tumour Expression of Signaling

NCT00881725 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00881725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00881725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Assessment of Neoadjuvant Intervention With Metformin Against Tumour Expression of Signaling
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2009
Completion date
June 30, 2012
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer